ASH 2023 Multiple Myeloma Review

Ashley Rosko, MD

Oncogeriatrics Medical Director Professor-Clinical of Medicine Division of Hematology The Ohio State University

3 February 2024 University of Nebraska



Conflicts of Interest

Research support Sanofi FDA ODAC Advisory Board Consultancy Curio Science Speaking ASH, ASTCT

Myeloma ASH 2023 Review

Objectives

1. Highlight ASH 2023 Myeloma practice 'Changing' or 'Influencing' abstracts.



American Society of Hematology Helping hematologists conquer blood diseases worldwide




Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Lenalidomide-Dexamethasone as Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients Francesca Gay, M.D., Ph.D.


Peter Voorhees, M.D.

Levine Cancer Institute Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Measurable Residual Disease as a Surrogate Endpoint for Studies in Patients with Newly Diagnosed Myeloma



Impact of Treatment Effect on MRD and PFS




i²TEAMM initiative: Meta-analysis of trial and patient level data

CI=Confidence interval; HR=Hazard ratio; MRD=Measurable residual disease; NGF=Next generation flow cytometry; NGS=Next generation sequencing; OS=Overall survival; PFS=Progression-free survival

Munshi NC et al. Blood Adv 2020;4:5988-5999


Paiva B et al. Blood Adv 2023 Aug:Online ahead of print





IsKia EMN24 Study Design

42 active sites; enrollment: Oct 7, 2020 - Nov 15, 2021



American Society of Hematology

TE, transplant-eligible; NDMM, newly diagnosed multiple myeloma; FISH, fluorescence in situ hybridization; del, deletion; t, translocation; ISS, International Staging System stage; R, randomization; isa, isatuximab; K, carfilzomib; R, lenalidomide; d, dexamethasone; IV, intravenous; dd, days; cc, cycles; PO, orally; Cy, cyclophosphamide; G-CSF, granulocyte colony-stimulating factor; MEL, melphalan; ASCT, autologous stem-cell transplantation; MRD, minimal residual disease; NGS, next-generation sequencing; PFS, progression-free survival.

Patient characteristics


		isa-KRd n=151	KRd n=151	
Age, years	Median (IQR)	61 (55-66)	60 (54-63)	
Sex, n (%)	Female Male	72 (48) 79 (52)	67 (44) 84 (56)	
Cytogenetic risk	Standard risk	115 (82)	113 (81)	
as per IMWG, n (%)	High risk	25 (18)	26 (19)	1
High risk: t(4;14), t(14;16), or del(17p)	Missing	11	12	1
No. of HRCA risk:	0 HRCA	78 (56)	75 (54)	
0 vs. 1 vs. 2+ HRCA, n (%)	1 HRCA	49 (35)	49 (35)	
del(17p13.1), t(4;14) (p16.3;q32.3),	2+ HRCA	13 (9)	15 (11)	1
t(14;16) (q32.3;q23), gain(1q21), or amp(1q21)	Missing	11	12	1
	1	50 (35)	48 (34)	
B 166 - (9/)	11	82 (58)	85 (59)	
R-ISS, n (%)	10	10 (7)	10 (7)	1
	Missing	9	8	1
	1	34 (24)	35 (25)	
	11	45 (32)	47 (34)	1
R2-ISS, n (%)	10	52 (37)	51 (37)	1
	IV	8 (6)	6 (4)	L
	Missing	12	12	1

Sonneveld P, et al. Blood. 2016 Jun 16;127(24):2955-62. doi: 10.1182/blood-2016-01-631200.

D'Agostino M et al. J Clin Oncol. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Erratum in: J Clin Oncol. 2022 Dec 1;40(34):4032.

Palumbo A, et al. J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267.

% are calculated on the number of patients whose data were available.; % may not total 100 because of rounding




Isa, isatoximab; K, carfilzomib; R, lenalidomide; d, dexamethasone; IOR, interquartile range; IMWG, International Myeloma Working Group; t, translocation; del, deletion; No., number; HRCA, high-risk cytogenetic abnormalities; amp, amplification; R-ISS, Revised International Staging System stage; R2-ISS, Second Revision of the International Staging System stage.

Primary Endpoint: Post-consolidation MRD negativity (ITT analysis)

NGS, 10⁻⁵

NGS, 10⁻⁶




≥VGPR after consolidation was 94% in both arms; ≥CR 74% vs 72% and sCR 64% vs 67% in the IsaKRd vs KRd arms.


High MRD compliance and sample quality (97-100% of sample evaluable at 10⁻⁵ and 10⁻⁶ cut off.

Consistent MRD results were detected by next-generation flow

In the logistic regression analysis, ORs, 95% CIs, and p-values were adjusted for stratification factor.



MRD negativity rates improved over time (10⁻⁵)



Safety analysis: treatment-related adverse events

	isa-KRd	(n=151)	KRd (n=151)		
	Any grade, n (%)	Grade 3-4, n (%)	Any grade, n(%)	Grade 3-4, n (%	
Pts with ≥1 hematologic toxicity	83 (55)	61 (40)	67 (44)	46 (30)	
Anemia	32 (21)	5 (3)	28 (19)	5 (3)	
Neutropenia	62 (41)	55 (36)*	39 (26)	33 (22)*	
Thrombocytopenia	51 (34)	22 (15)	38 (25)	25 (17)	
Pts with ≥1 Non-Hematologic toxicity	136 (90)	61 (41)	129 (85)	56 (3 <mark>7</mark>)	
Infections (excluding COVID19)	55 (36)	23 (15)	49 (32)	17 (11)	
Asthenia/fatigue	37 (25)	5 (3)	40 (26)	3 (2)	
Dyspnea	20 (13)	2 (1)	9 (6)	1 (<1)	
Rash	33 (22)	5 (3)	40 (26)	5 (3)	
Peripheral neuropathy	22 (15)	0	25 (17)	0	
Infusion-related reactions	30 (20)	5 (3)	2 (1)	0	
Cardiac disorders	11 (7)	1 (<1)	19 (13)	5 (3)	
Vascular disorders	29 (19)	7 (5)	33 (22)	15 (10)	
Hypertension	5 (3)	2 (1)	6 (4)	3 (2)	
Thromboembolism	12 (8)	4 (3)	16 (11)	9 (6)	
Gastrointestinal disorders	79 (52)	10 (7)	73 (48)	8 (5)	
Nausea	36 (24)	4 (3)	31 (21)	2 (1)	
Vomiting	18 (12)	2 (1)	12 (8)	1 (<1)	
Diarrhea	41 (27)	6 (4)	37 (25)	5 (3)	

Key Points Isa-KRD unlikely to supplant D-VRD ³⁹ (26 ENDURANCE¹⁾ MRD primary endpoint?

*p-value =0.008



Phase 3 Randomized Study of Daratumumab + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus VRd Alone in Patients With Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Stem Cell Transplantation: Primary Results of the PERSEUS Trial*

*ClinicalTrials.gov Identifier: NCT03710603; sponsored by EMN in collaboration with Janssen Research & Development, LLC.

Pieter Sonneveld,¹ Meletios A. Dimopoulos,² Mario Boccadoro,³ Hang Quach,⁴ P. Joy Ho,⁵ Meral Beksac,⁶ Cyrille Hulin,⁷ Elisabetta Antonioli,⁸ Xavier Leleu,⁹ Silvia Mangiacavalli,¹⁰ Aurore Perrot,¹¹ Michele Cavo,¹² Angelo Belotti,¹³ Annemiek Broijl,¹ Francesca Gay,¹⁴ Roberto Mina,¹⁴ Inger S. Nijhof,^{15,16} Niels W.C.J. van de Donk,¹⁵ Eirini Katodritou,¹⁷ Fredrik Schjesvold,¹⁸ Anna Sureda Balari,¹⁹ Laura Rosiñol,²⁰ Michel Delforge,²¹ Wilfried Roeloffzen,²² Tobias Silzle,²³ Annette Vangsted,²⁴ Hermann Einsele,²⁵ Andrew Spencer,²⁶ Roman Hajek,²⁷ Artur Jurczyszyn,²⁸ Sarah Lonergan,¹ Tahamtan Ahmadi,²⁹ Yanfang Liu,³⁰ Jianping Wang,³⁰ Diego Vieyra,³⁰ Emilie M.J. van Brummelen,³⁰ Veronique Vanquickelberghe,³⁰ Anna Sitthi-Amorn,³⁰ Carla J. de Boer,³⁰ Robin Carson,³⁰ Paula Rodriguez-Otero,³¹ Joan Bladé,³² Philippe Moreau³³

¹Erasmus MC Cancer Institute, Rotterdam, The Netherlands; ²National and Kapodistrian University of Athens, Athens, Greece; ³Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy; "University of Melbourne, St Vincent's Hospital, Melbourne, Australia; ⁴Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW, Australia; ⁴Matara University, Ankara, Turkey; ⁷Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France; ⁴⁰Department of Hematology, Careggi Hospital and University of Florence, Firenze, Italy; ⁴University of Potiers, CHU and Insern 1313, Potiers, France; ¹⁰Hematology Division, IRCCS Fondazione Policinico San Matteo, Pavia, Italy: ¹⁰University of Potiers, CHU and Insern 1313, Potiers, France; ¹⁰Hematology Division, IRCCS Fondazione Policinico San Matteo, Pavia, Italy: ¹⁰University of Potiers, CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France; ¹⁰IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Italy: ¹¹Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy; ¹¹Division of Hematology 1, AOU Città della Salute e della Scienza di Torino, and Department of Meentology and Health Sciences, University of Torino, Italy: ¹¹Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece; ¹⁸Oslo Myeloma Center, Department of Hematology, and KG Jebsen Center for B-cell Malignancies, University of Oslo, Oslo, Norway; ¹⁰Hematology Department, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain; ²⁰Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Switzerland; ³⁰Department of Hematology, Rightospitalet, Copenhagen, Denmark; ²⁰Department of Internal Medicine II, University Hospita

Presented by P Sonneveld at the 65th American Society of Hematology (ASH) Annual Meeting; December 9-12, 2023; San Diego, CA, USA




https://www.congresshub.com/Oncology/ ASH2023/Daratumumab/Sonneveld

The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.



PERSEUS: Study Design



ECOG PS, Eastern Cooperative Oncology Group performance status; V, bortezomib; SC, subcutaneous; PO, oral; d, dexamethasone; IV, intravenous; QW, weekly; Q2W, every 2 weeks; PD, progressive disease; Q4W, every 4 weeks; MRD, minimal residual disease; OS, overall survival; ISS, International Staging System; rHuPH20, recombinant human hyaluronidase PH20; IMWG, International Myeloma Working Group; VGPR, very good partial response. *Stratified by ISS stage and cytogenetic risk. *DARA 1,800 mg co-formulated with rHuPH20 (2,000 U/mL; ENHANZE* drug delivery technology, Halozyme, Inc., San Diego, CA, USA). *Response and disease progression were assessed using a computerized algorithm based on IMWG response criteria. *MRD was assessed using the clonoSEQ assay (v.2.0; Adaptive Biotechnologies, Seattle, WA, USA) in patients with ≥VGPR post-consolidation and at the time of suspected ≥CR. Overall, the MRD-negativity rate was defined as the proportion of patients who achieved both MRD negativity(10⁻⁵ threshold) and ≥CR at any time



Presented by P Sonneveld at the 65th American Society of Hematology (ASH) Annual Meeting; December 9-12, 2023; San Diego, CA, USA

PERSEUS: PFS in Prespecified Subgroups

	D-VRd	VRd			
Subgroup	no. of progression events or	deaths/total no.		HR (95% CI)	
Sex					
Male		1/205			0.51 (0.34-0.77)
Female	14/144 4	2/149	· - ● !		0.29 (0.16-0.53)
Age					
<65 y		4/267	⊢ •i		0.30 (0.20-0.46)
≥65ý	20/94 1	9/87		├─── ┤	0.97 (0.52-1.81)
Race			i		
White		5/323		l	0.42 (0.30-0.60)
Other	3/25	8/31		⊢−− 1	0.40 (0.11-1.50)
ISS stage					
1	18/186 3	5/178			0.46 (0.26-0.81)
11	19/114 4	3/125			0.37 (0.22-0.64
111	13/55 2	25/50	·+ i		0.42 (0.22-0.83
Type of MM					
- ÍgG		8/185			0.36 (0.23-0.57)
Non-lgG	13/78 3	31/96	· · · · • · · · · · ·		0.46 (0.24-0.88)
Cytogenetic risk			1	l	
Standard risk		2/266			0.35 (0.22-0.56
High risk		38/78	⊢ ● (0.59 (0.36-0.99
Indeterminate	1/15	3/10 🔶	•		0.16 (0.02-1.56)
ECOG PS					
0		0/230			0.42 (0.27-0.66)
≥1	22/134 4	3/124		l	0.41 (0.25-0.69)
		<u> </u>	<u> </u>		
		0.1		1 10	
		4	Favors D-VRd	Favors VRd	


PFS was improved with D-VRd versus VRd across clinically relevant subgroups



The subgroup analysis for type of MM was performed on data from patients who had measurable disease in serum. Cytogenetic risk was assessed by fluorescence in situ hybridization; high risk was defined as the presence of del(17p), t(4;14), and/or t(14;16).

Presented by P Sonneveld at the 65th American Society of Hematology (ASH) Annual Meeting; December 9-12, 2023; San Diego, CA, USA

PERSEUS: Progression-free Survival



58% reduction in the risk of progression or death in patients receiving D-VRd



HR, hazard ratio; CI, confidence interval.

Presented by P Sonneveld at the 65th American Society of Hematology (ASH) Annual Meeting; December 9-12, 2023; San Diego, CA, USA

PERSEUS: Safety

	D-V (n=∶		VRd (n = 347)		
Event, n (%)ª	Any grade	Grade 3 or 4	Any grade	Grade 3 or 4	
HEMATOLOGIC					
Neutropenia	243 (69.2)	218(62.1)	204 (58.8)	177 (51.0)	
Thrombocytopenia	170 (48.4)	102 (29.1)	119 (34.3)	60 (17.3)	
Anemia	78 (22.2)	21 (6.0)	72 (20.7)	22 (6.3)	
Febrile neutropenia	34 (9.7)	33 (9.4)	38 (11.0)	35 (10.1)	
NON-HEMATOLOGIC					
Diarrhea	214 (61.0)	37 (10.5)	188 (54.2)	27 (7.8)	
Peripheral sensory neuropathy	188 (53.6)	15(4.3)	179 (51.6)	14(4.0)	
Constipation	119 (33.9)	8 (2.3)	118 (34.0)	6 (1.7)	
Pyrexia	111 (31.6)	8 (2.3)	109 (31.4)	9 (2.6)	
Insomnia	95 (27.1)	8 (2.3)	61 (17.6)	6 (1.7)	
Asthenia	94 (26.8)	12 (3.4)	89 (25.6)	9 (2.6)	
Cough	85 (24.2)	1 (0.3)	51 (14.7)	0	
Fatigue	84 (23.9)	10 (2.8)	92 (26.5)	18 (5.2)	
Rash	82 (23.4)	9 (2.6)	94 (27.1)	17 (4.9)	
Back pain	80 (22.8)	2 (0.6)	66 (19.0)	1 (0.3)	
Peripheral edema	72 (20.5)	4 (1.1)	74 (21.3)	1 (0.3)	
Nausea	71 (20.2)	2 (0.6)	58 (16.7)	2 (0.6)	
Infections	305 (86.9)	124 (35.3)	266 (76.7)	95 (27.4)	
COVID-19	123 (35.0)	12 (3.4)	83 (23.9)	4 (1.2)	
Upper respiratory tract infection	111 (31.6)	2 (0.6)	87 (25.1)	6 (1.7)	
Pneumonia	64 (18.2)	37 (10.5)	38 (11.0)	21 (6.1)	



TEAE, treatment-emergent adverse event. aTEAEs of any grade reported in 220% of patients in either treatment group and grade 3 or 4 TEAEs reported in 210% of patients in either treatment group.

Presented by P Sonneveld at the 65th American Society of Hematology(ASH) Annual Meeting; December 9-12, 2023; San Diego, CA, USA

Table S6. Overview of Adverse Events by Age Subgroup in the Safety Population.*

		D-V	Rd	1.1		V	Rd		
	<50 y (n = 53)	50-<65 y (n = 205)	≥65 y (n = 93)	Total (n = 351)	<50 y (n = 53)	50 60 (n = 207)	(n = 87)	ints (n = 347)	
Treatment-emergent adverse event -						•	D-V	RD S	SOC
no. (%)	-						Nuo	nco	C •
Any grade	52 (98.1)	204 (99.5)	93 (100.0)	349 (99.4)	52 (98.1)	205 (99.0)	8, (10).6,	nce	.
Grade 3	30 (56.6)	116 (56.6)	47 (50.5)	193 (55.0)	29 (54.7)	122 (58.9)	o ^s rac	ticè	vs trials
Grade 4	15 (28.3)	64 (31.2)	38 (40.9)	117 (33.3)	11 (20.8)	46 (22.2)	26 (29.9)	83 (23.9)	
Treatment-emergent adverse event	2 (3.8)	17 (8.3)	12 (12.9)	31 (8.8)	6 (11.3)	31,15.9)	(vel	cade	,
leading to treatment discontinuation - no. (%)							cons	solic	lation)
Treatment-emergent adverse event leading to death – no. (%)	0	8 (3.9)	5 (5.4)	13 (3.7)	2 (3.8)	10 (4.8)	4 (4.6)	16 (4.6)	

D-VRd denotes subcutaneous daratumumab plus bortezomib/lenalidomide/dexamethasone. VRd denotes bortezomib/lenalidomide/

dexamethasone.


*The safety population included patients who received at least one dose of study treatment.

Sonneveld et al. NEJM 12 Dec 2023


GEM-2017FIT: Induction therapy with VMP/Rd vs KRd or Dara-KRd 18c followed by consolidation and maintenance therapy with Dara and Len: phase III, multicenter, randomized trial for elderly FIT NDMM aged between 65 and 80 years

María-Victoria Mateos, Bruno Paiva, Teresa Cedena, Noemí Puig, Anna Sureda, Albert Oriol, Enrique-M Ocio, Laura Rosiñol, Yolanda González, Joan Bargay, Esther González, Miguel Teodoro Hernández, Angel Payer, Alexia Suarez, María-Jesús Blanchard, Sebastián Garzón, Felipe Casado, Valentín Cabañas, Jaime Pérez de Oteyza, Mercedes Gironella, Joaquín Martínez, Ana Isabel Teruel, Pilar Delgado, Elena Prieto, Juan-José Lahuerta, Joan Bladé, Jesús San Miguel





GEM2017FIT phase 3 trial: VMP-Rd 18c vs KRd or D-KRd 18c in NDMM-TIE and up to 80 years



- VMP-Rd in patients younger than 80 years resulted in a MRD-ve rate of 20%
- Hypothesis was to increase the MRDve rate up to 35% in the two experimental arms
- Sample size required was 462 patients

Primary end-point: MRD-ve by NGF at 10⁻⁵ after 18 cycles comparing VMP-Rd with KRd and VMP-Rd with D-KRd





GEM2017 phase 3 trial in NDMM TIE FIT

Fitness was evaluated based on the chronological age (up to 80 years) and the Geriatric Assessment in Hematology (GAH) score


Dimension	Measurement	Range of score	Cut-off point	Coefficients
No. of drugs	Medication count of drugs of current use.	Continuous	≥ 5	2
Gait speed	Double determination of gait speed at usual pace over a 4 meter course	Continuous	< 0.8 m/s	13
Mood	In the last week, did you feel depressed? (CES-D)	Never, rarely, or occasionally (no more than 2 days); frequently, most of the time or all time (3-7 days)	Frequently, most of the time or all time (3-7 days)	4
ADL	Item no. 4 of the VES-13 Instrument: <i>Do you have any difficulty in…?</i> <i>Do you need any help in your daily living?</i> <i>Do you have a caregiver?</i>	Yes / No	Needs help in at least one area	22
Subjective Health Status	Compared to other people your age, would you say your health is? (VES-13 Instrument:)	Poor, fair, good, very good, or excellent	Poor and fair	6
Nutrition	MNA-SF	0-10	≤ 8	40
Viental Status	SPMSQ	Right / Wrong	≥ 3 errors	5
Comorbidities	Prognostic Index for 4-year Mortality in Older Adults	0-10	≥ 3	5

ADL activities of daily living, CES-D centre for epidemiological studies depression scale, DM diabetes mellitus, MNA-SF mini-nutritional assessment questionnaire, SPMSQ short portable mental status questionnaire, VES-13 13-item vulnerable elders survey.

AUC (95% CI)	Cut-off point	Sensitivity (95% CI)	Specificity (95% Cl)	PPV (95% Cl)	NPV (95% CI)
	3.2	96.3% (87.5-98.98%)	9.3% (3.7-21.6%)	57.1% (46.3-67.5%)	66.7% (22.3-95.7%)
0.625 (0.512 - 0.739)	41.6	68.5% (55.3-79.3%)	55.8% (41.1-69.6%)	66.1% (52.2-87.2%)	55.8% (41.1-69.6%)
	84.6	3.7% (1.0-12.5%)	95.3% (84.5-98.7%)	50.0% (6.8-93.2%)	44.1% (33.8-54.8%)

Data are expressed as n, unless otherwise stated. AUC area under the curve, CI confidence interval, NPV negative predictive value, PPV positive predictive value.

• The sum of the GAH scale score ranges from 0 to 94, with a cut-off point set at 42 (Figure 1).



30 ítems in 10-12 minutes. Lower score \rightarrow Better status







GEM2017 phase 3 trial in NDMM TIE FIT: MRD-ve rate at 10-5 after 18 induction cycles in the evaluable population: Primary endpoint Key Points OR= 3.95, p<0,0005 OR= 2.68, p<0,0005 Marks the end of VMP 90% 84% 79% 75% 80% 66% 70% 60% Axis Title 40% 33% 25% 30% 20% 10% 0% Dara-KRd (n=112) VMP-Rd (n=127) KRd (n=111)

MRD-ve 10-5 MRD-ve 10-6

Evaluable population included all patients who have completed the 18 induction cycles as well as those who discontinued early because of progressive disease and the MRD was considered as positive

BSAL





GEM2017 phase 3 trial in NDMM TIE FIT: Early discontinuations


Discontinuation during induction	VMP-Rd (n=49)	Toxicity leading to discontinuation	KRD (n=43)	Toxicity leading to D-KRd Toxicity leading to discontinuation $Key^{(n=4}Points$
Time to early discontinuation	9.9 (0.5-18.9)		8.4 (0.3-18.4)	 4.0 (0.03-18.8) 4- drug induction
Toxicity	8 (16%)	PN G3 (1), cardiac tox (1), GI tox (2), renal tox (1),cytopenias (1), pulmonar tox (1), len intolerance (1)	14 (32%) OR. 2.47, p=0.06	Cardiac tox (3), Thrombot Toxic(tx) and stoxic(), Len-related events (2), rash (2), renal tox (3), hepatitis (1), respiratory infection (1), thromboper in elated deat toxicity (1) (1), TLS (1)
Toxicity-related death	7 (14%)	Cardiac arrest (2) Sepsis (2) Respiratory infection (3)	5 (12%) OR: 0.78, p=0.7	Sepsis (2), Covid-19 (1), GMMG3%CONCEPTretrial Infection (1), Guillen BanGMMG-3CONCEPTretrial sindrome (1) Primary endpoint MRD
GAH ≥ 20	25 (51%)		17 (40%) OR: 0.62, p=0.2	26 (67%) OR: 1.92, p=0.1

- Toxicity in the KRd arm leading to discontinuation was higher tan VMP-Rd but there was not any trend to specific toxicity
- Toxicity in the D-KRd arm leading to discontinuation was similar to VMP-Rd with not any trend to specific toxicity
- Toxicity-related deaths in the three arms were because of infections as the most frequent reason
- There is a trend for patients with GAH ≥ 20 to discontinue because of toxicity or toxicity-related death and especifically, higher scores concentrated on gait speed and nutrition.









Relapsed Multiple Myeloma



American Society of Hematology Helping hematologists conquer blood diseases worldwide



Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study

Yang Song^{1*}, Jin Seok Kim^{2*}, CS Chim,^{3*}, Je-Jung Lee^{4*}, Sung-Soo Yoon⁵, Soo Chin Ng, FRCP⁶, Gin Gin Gan^{7*}, Hiroshi Handa⁸, Wei-Ying Jen,^{1*}, Xinhua Li^{9*}, Yogesh Mahadev Pokharkar^{9*}, Brian GM Durie¹⁰ and **Wee-Joo Chng¹**

¹Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore; ²Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of (South); ³Comprehensive Oncology Centre, 3/F, Li Shu Fan Block, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong, China; ⁴Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of (South); ⁵Department of Hemato-Oncology, Seoul National University Hospital, Seoul, Korea, Republic of (South); ⁶Subang Jaya Medical Center, Petaling Jaya, Malaysia; ⁷University of Malaya, Kuala Lumpur, Malaysia; ⁸Department of Hematology, Gunma University Hospital, Maebashi, Gunma, Japan; ⁹Singapore Clinical Research Institute, Singapore, Singapore; ¹⁰Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA


Prior Therapies


Parameters, N(%) / Median [range]	PCD (N=62)	PD (N=60)
No. of lines of prior treatment	3 [1-6]	3 [1-6]
Previously received therapies (i) Bortezomib (ii) Carfilzomib (iii) Ixazomib (iv) Lenalidomide (v) Thalidomide (vi) Cyclophosphamide	47 (75.8) 24 (38.7) 7 (11.3) 61 (98.4) 34 (54.8) 29 (46.8)	46 (76.7) 18 (30.0) 8 (13.3) 60 (100) 28 (46.7) 19 (31.7)
Prior Autologous Stem Cell Transplant	27 (43.5)	24 (40.0)




Methods

- Patients randomised in a 1:1 ratio to receive PCD or PD
- Dosing schedule for PCD
 - 4-weekly: pom 4mg day 1 21, dexamethasone 40mg once a week, cyclophosphamide 400mg weekly for 3 weeks.
- Dosing schedule for PD
 - 4-weekly: pom 4mg day 1 21, dexamethasone 40mg once a week.






PCD has longer Duration of Response (DOR)




Median DOR was 12.0 months (95% Cl, 7.2 – not reached, NR) in the PCD arm and 5.7 months (95% Cl, 3.7 – 9.7) in the PD arm (HR 0.41, 95% Cl, 0.20 – 0.87).




PCD produce better and deeper response



- ORR was 61.3% (95% CI, 41.0 69.7) in the PCD arm and 38.3% (95% CI, 19.5 – 44.5) in the PD arm
- Difference 23% (95% Cl, 6.5 40.2, p = 0.007)



PFS is significantly improved by PCD



Kaplan-Meier plot – progression free survival (PFS) Efficacy Evaluable Population Key Points Median follow-up of 13.5 (IQR, 8.7 – 24.0) monthsAll oral PCD

- Median PFS was 10.9 (95% CI, 7.1 27.7) months DO R Conversion of the 5.8 (95% CI, 4.4 – 6.9) months for PD Hazard ratio (HR) 0.45 (55% CI, 0.27-
- Hazard ratio (HR) 0.45 (55% CI, 0.27-0.69); p < 0.001)

American Society of Hematology






Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long term follow Up results of the Randomized GMMG Phase III Multicenter Trial ReLApsE

<u>Marc-Andrea Baertsch, MD^{1,2}</u>, Jana Schlenzka, MD¹, Thomas Hielscher³, Marc-Steffen Raab, MD^{1,2,4}, Sandra Sauer¹, MD, Maximilian Merz, MD⁵, Elias Karl Mai, MD¹, Carsten Müller-Tidow, MD^{1,4}, Steffen Luntz, MD⁶, Anna Jauch, PhD⁷, Peter Brossart, MD⁸, Martin Goerner, MD⁹, Stefan Klein, MD¹⁰, Bertram Glass, MD¹¹, Peter Reimer, MD¹², Ullrich Graeven, MD¹³, Roland Fenk, MD PhD¹⁴, Mathias Haenel, MD¹⁵, Ivana von Metzler, MD¹⁶, Hans W. Lindemann, MD¹⁷, Christof Scheid, MD¹⁸, Axel Nogai, MD¹⁹, Hans Salwender, MD²⁰, Richard Noppeney, MD²¹, Britta Besemer, MD²², Katja Weisel, MD²³, Hartmut Goldschmidt, MD^{1,4}

65th ASH Annual Meeting, San Diego, December 11 2023



MG

GMMG ReLApsE trial - Flow chart

ReLApsE - Baseline characteristics



HD


	arm A (n=138) n (%)	arm B (n=139) n (%)		arm A (n=138) n (%)	arm B (n=139) n (%)
Age [years]	62.2 (41.9; 74.5)	61.3 (29.9; 74.7)	Interval diagnosis to	No since in	S. L. M. M. S.
Sex Female	54 (39)	60 (43)	randomization [years]	4.1 (0.7-16.5)	3.9 (0.2-19.4)
WHO PS 0 1 2	105 (76) 32 (23) 1 (1)	96 (69) 43 (31) 0	Prior lines of therapy 1 2 3	129 (94) 8 (6) 1 (1)	131 (94) 5 (4) 3 (2)
ISS stage I II	77/129 (60) 40/129 (31) 12/129 (9)	82/131 (63) 32/131 (24) 17/131 (13)	Frontline HDCT/ASCT Single Tandem	130 (94) 71 (55) 59 (45)	129 (93) 83 (64) 46 (36)
Cytogenetics t(4;14) t(14;16) del13q14 del17p13	10/99 (10) 0/97 (0) 45/104 (43) 15/107 (14)	19/94 (20) 2/90 (2) 59/97 (61) 14/98 (14)	Prior therapy Bortezomib Thalidomide Lenalidomide Interferone	106 (77) 25 (18) 18 (13) 9 (7)	107 (77) 31 (22) 12 (9) 9 (6)
gain1q (>3 copies) High risk*	12/105 (11) 31/98 (32)	11/97 (11) 39/91 (43)	Chemoth. only	10 (7)	14 (10)


*High risk cytogenetic aberrations: t(4;14), t(14;16), del17p13, gain1q (>3 copies)

Goldschmidt H*, Baertsch MA* et al., Leukemia, 2021

ReLApsE - Survival - LTFU analysis










No survival benefit in long term follow up analysis from randomization

ReLApsE - Drop outs before salvage ASCT



29% of patients (41/139) did not receive salvage transplant



MG

GM


Subgroups OS

Absence of OS benefit is consistent across key patient subgroups

			Favo	rs		
		a	m B	arm A		
Subgroup	p-value	-	_		•	p-value for interaction
ISS						0.1434
Arm B vs. Arm A, ISS I	0.148					
Arm B vs. Arm A, ISS II	0.879		-+	-		
Arm B vs. Arm A, ISS III	0.223			•	-	
R-ISS			12.1			0.2652
Arm B vs. Arm A, R-ISS I	0.088		•			
Arm B vs. Arm A, R-ISS II	0.716			-		
Arm B vs. Arm A, R-ISS III	0.555		•	_		
TTP1*			100			0.7124
Arm B vs. Arm A, subgroup TTP (12,24]	0.604		-	-		
Arm B vs. Arm A, subgroup TTP (24,48]	0.965			-		
Arm B vs. Arm A, subgroup TTP >48	0.362					
high.risk.hd			1.1.1			0.7834
Arm B vs. Arm A, high risk yes	0.959			-		
Arm B vs. Arm A, high risk no	0.704			-		
Arm B vs. Arm A, high risk NA	0.203	1.0	-	•		
Age			10.1			0.8915
Arm B vs. Arm A, age<65	0.502			-		
Arm B vs. Arm A, age>=65	0.782			-		
Renal function			1.1			0.1399
Arm B vs. Arm A, MDRD <60	0.274		-			
Arm B vs. Arm A, MDRD >= 60	0.255			1.1		
LDH (baseline)			10.1			0.0268
Arm B vs. Arm A, LDH below ULN	0.136					
Arm B vs. Arm A, LDH above ULN	0.154		-	-		
Frontline transplant (single/tandem)		10.00			0.6651
Arm B vs. A, subgroup prior single TPL	0.229					
Arm B vs. A, subgroup prior tandem TPL	0,662		-	-		
Prior lines of treatment			1.1			0.4944
Arm B vs. Arm A, 1 prior therapy lines	0.562			6 0.2		
Arm B vs. Arm A, >1 prior therapy line	0.5		-	_		
Prior maintenance treatment			1.11			0.9859
Arm B vs. Arm A, no ET	0.519		-	-		
Arm B vs. Arm A, ET	0.656					
		1	1 1	1		
			0.50 1.0		4.0	
		mazard f	atio for OS i	in subgrou	ps, III	



UK



Time to progression after frontline transplant is a prognostic factor for survival in both treatment arms



Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel vs Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma After 1–3 Lines of Therapy

Roberto Mina¹, Anne K Mylin², Hisayuki Yokoyama³, Hila Magen⁴, Winfried Alsdorf⁵, Monique C Minnema⁶, Leyla Shune⁷, Iris Isufi⁸, Simon J Harrison⁹⁻¹¹, Urvi A Shah¹², Jordan M Schecter¹³, Nikoletta Lendvai¹³, Katharine S Gries¹⁴, Eva G Katz¹⁴, Ana Slaughter¹⁵, Carolina Lonardi¹⁶, Jane Gilbert¹⁷, Quanlin Li¹⁸, William Deraedt¹⁹, Octavio Costa Filho²⁰, Nitin Patel²⁰, Lionel Karlin²¹, Katja Weisel⁵

¹University of Turin, Turin, Italy; ²Rigshospitalet, Copenhagen, Denmark; ³Tohoku University Graduate School of Medicine, Sendai, Japan; ⁴Chaim Sheba Medical Center, Ramat-Gan, Sackler Faculty of Medicine, Tel Aviv University, Israel; ⁵University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ⁶University Medical Center Utrecht, Utrecht, Netherlands; ⁷The University of Kansas Medical Center, Kansas City, KS, USA; ⁸Yale School of Medicine, Yale University, New Haven, CT, USA; ⁹Peter MacCallum Cancer Centre, Melbourne, Australia; ¹⁰Royal Melbourne Hospital, Melbourne, Australia; ¹¹Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia; ¹²Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; ¹³Janssen Research & Development, Raritan, NJ, USA; ¹⁴Janssen Global Services, LLC, Raritan, NJ, USA; ¹⁵Cilag GmbH International, Zug, Switzerland; ¹⁶Janssen, Buenos Aires, Argentina; ¹⁷Janssen Research & Development, High Wycombe, UK; ¹⁸Janssen Research & Development, Apex, NC, USA; ¹⁹Janssen Research & Development, Beerse, Belgium; ²⁰Legend Biotech USA Inc., Somerset, NJ, USA; ²¹Centre Hospitalier Lyon Sud, Pierre-Bénite, France

Presented by R Mina at the 65th American Society of Hematology (ASH) Annual Meeting; December 9–12, 2023; San Diego, CA, USA


https://www.congresshub.com/Oncology/ ASH2023/Cilta-Cel/Mina

The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.



CARTITUDE-4: Introduction

- Cilta-cel is a CAR-T cell therapy approved for the treatment of RRMM after \geq 4 LOT in the US (\geq 3 LOT in the EU)^{1,2}
- In the phase 1b/2 CARTITUDE-1 trial, a single cilta-cel infusion in heavily pretreated patients:
 - Led to deep and durable responses alongside a manageable safety profile³
 - Improved HRQoL, including emotional and physical functioning, and reduced MM-related symptoms⁴
- The phase 3 CARTITUDE-4 trial compared cilta-cel with SOC in patients with lenalidomide-refractory MM after 1–3 LOT^{5,6}
 - A single cilta-cel infusion significantly improved PFS and increased the rate and depth of response vs SOC^{5,6}




Here, we present patient-reported outcomes from patients randomized to cilta-cel vs SOC in CARTITUDE-4 at 15.9-month median follow-up

^aAt the clinical cut-off of November 1, 2022, median follow-up from randomization was 15.9 months. cilta-cel, ciltacabtagene autoleucel; EU, European Union; HR, hazard ratio; HRQoL, health-related quality of life; LOT, line of therapy; MM, multiple myeloma; NE, not estimable; NR, not reached; PFS, progression-free survival; RRMM, relapsed refractory MM; SOC, standard of care. 1. CARVYKTI® (ciltacabtagene autoleucel). Prescribing information. Janssen Biotech, Inc.; 2023. Accessed November 27, 2023. https://www.fda.gov/media/156560/download. 2. CARVYKTI® (ciltacabtagene autoleucel). European Medicines Agency. Orphan maintenance assessment report. June 7, 2022. Accessed November 27, 2023. https://www.ema.europa.eu/en/documents/product-information/carvykti-epar-product-information_en.pdf. 3. Martin T, et al. *J Clin Oncol* 2023;41:1265-74. 4. Martin T, et al. *Lancet Haematol* 2022;9:e897-905. 5. San-Miguel J, et al. *N Engl J Med* 2023;389:335-47. 6. Dhakal B, et al. *J Clin Oncol* 2023;41(suppl 17):LBA106.



Presented by R Mina at the 65th American Society of Hematology (ASH) Annual Meeting; December 9–12, 2023; San Diego, CA, USA

CARTITUDE-4: Study Design and Endpoints^{1,2}



^aPhysicians' choice. ^bAdministered until disease progression. Time from randomization to disease progression/death. BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; cilta-cel, ciltacabtagene autoleucel; CR, complete response; DPd, daratumumab, pomalidomide, and dexamethasone; ECOG PS, Eastern Cooperative Oncology Group performance status; IMiD, immunomodulatory drug; ISS, International Staging System; len, lenalidomide; LOT, line of therapy; MM, multiple myeloma; MRD, minimal residual disease; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PI, proteasome inhibitor; PVd, pomalidomide, bortezomib, and dexamethasone; SOC, standard of care.

1. San-Miguel J, et al. N Engl J Med 2023;389:335-47. 2. Dhakal B, et al. J Clin Oncol 2023;41(suppl 17):LBA106.

Presented by R Mina at the 65th American Society of Hematology (ASH) Annual Meeting; December 9–12, 2023; San Diego, CA, USA



CARTITUDE-4: PRO Assessments

- PRO assessments were administered at baseline^a and at months 3, 6, 9, 12, 18, and 24 in both arms
 - Change from baseline^a was calculated for patients with assessments at baseline^a and at the given time point
- EORTC QLQ-C30, EQ-5D-5L, and MySIm-Q questionnaires were administered to all patients until disease progression^b

EORTC QLQ-C30^{1,c}

- Cancer-specific questionnaire
 Scores range from 0–100
- Global health status scale
- 3 symptom scales
 - Fatigue
 - Nausea and vomiting
 - Pain

- 5 functional scales
 - Physical
 - Role
 - Emotional
 - Cognitive
 - Social

- EQ-5D-5L²
- Generic measurement of health
- Visual analogue scale
 - Patients' self-rated health between 100 (best imaginable health) and 0 (worst imaginable health)

MySIm-Q^{3,d}

- MM-specific questionnaire
 - Assesses 17 single items across
 8 domains on a 5-point verbal scale
- Symptom subscale
 - Assesses pain, neuropathy, fatigue, digestive, and cognitive symptom domains
- Impact subscale
 - Assesses activity, social, and emotional impact domains

^aBaseline is defined as apheresis for cilta-cel arm and cycle 1 day 1 for SOC arm. ^bEQ-5D-5L collected post disease progression every 16 weeks until end of study. ^cHigher scores represent better health-related quality of life and better functioning (global health status and functional scales) or more/worse symptoms (symptom scales and single items). ^dHigher scores represent more/worse symptoms and impact. cilta-cel, ciltacabtagene autoleucel; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30-item; EQ-5D-5L, EuroQoL 5-Dimension 5-Level; MM, multiple myeloma; MySIm-Q, Multiple Myeloma Symptom and Impact Questionnaire; PRO, patient-reported outcome.



1. Aaronson NK, et al. J Natl Cancer Inst 1993;85:365-76. 2. Herdman M, et al. Qual Life Res 2011;20:1727-36. 3. Gries KS, et al. Value Health 2021;24:1807-19.



CARTITUDE-4: Baseline PRO Scores Were Generally Similar in Both Treatment Arms

Key Points

- Global health status scores at baseline for both treatment arms were lower than benchmark scores for the general population,^{1,a} suggesting worse overall health
- Physical, role, and social functioning, as well as pain and fatigue symptoms, showed that most MM-relevant scores at baseline were worse in CARTITUDE-4 than in the general population^{1,a}

	Cilta-cel (n=191)	MM pat	gerera poruSion ^{1,a}
EORTC QLQ-C30, ^b mean (SD)			
Global health status	60. <mark>7</mark> (22.4)	$6^{2}4^{(216)}$ rt	-661(217) of
Functional scales		-répôrt s	
Cognitive functioning	83. <mark>4</mark> (19.9)	83.6 (18.7)	84.8 (21.3)
Emotional functioning	74. <mark>6</mark> (20.2)	-the end of the second	74.2 (24.7)
Physical functioning	74.2 (23.2)		S G 5.1 (18.9)
Role functioning	66. <mark>4 (30.1)</mark>	70.6 (26.2)	84.3 (24.6)
Social functioning	72.1 (28.1) ^d	-HRQoL	$c c \delta^2 r^4 \delta c$
Symptom scales/items			SCULES
Fatigue	37.3 (26.2) ^d	35.9 (24.3) ^e	29.5 (25.5)
Nausea and vomiting	6.3 (13.6) ^e	acroc	5.9 (16.0)
Pain	37. <mark>2 (29.9)</mark>	across	23.5 (27.1)
EQ-5D-5L, ^b mean (SD)			
Visual analogue scale	65. <mark>3</mark> (19.9)	maligna	nciac
MySIm-Q, ^g mean (SD)		inangna	
Total symptom subscale	1.06 (0.69)	0.97 (0.60) ^h	NA
Total impact subscale	1.31 (0.93)	1.16 (0.82) ^h	NA


^aGeneral population ≥18 years of age from 11 European countries. ^bScores range from 0–100; higher scores represent better health-related quality of life and better functioning (global health status, functional scales, and visual analogue scale) or more/worse symptoms (symptom scales). ^cn=189. ^dn=190. ^en=188. ^fn=182. ^g5-point scale; higher scores represent more/worse symptoms or impacts. ^hn=183. EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30-item; EQ-5D-5L, EuroQoL 5-Dimension 5-Level; MM, multiple myeloma; MySIm-Q, Multiple Myeloma Symptom and Impact Questionnaire; NA, not assessed; NR, not reported; PRO, patient-reported outcome; SOC, standard of care. 1. Nolte, S. et al. *Eur J Cancer* 2019;107:153-63.




Presented by R Mina at the 65th American Society of Hematology (ASH) Annual Meeting; December 9–12, 2023; San Diego, CA, USA

CARTITUDE-4: Clinically Meaningful Improvements in Global Health Status Score With Cilta-cel

- Global health status score improved over time in the cilta-cel arm but not the SOC arm CAR-T Sustained
 At month 12, 40% of patients in the cilta-cel arm and 24% in the SOC arm achieved a clinically meaningful improvement^{1, z, a}





Key Points

^aChange from baseline >10 points. ^bMixed-model for repeated measures analyses were conducted using data from patients with assessments at both baseline and the given time point. Baseline patient-reported outcome score and prognostic characteristics were included as covariates to balance arms and to adjust for confounders. Assessments after the start of subsequent therapy were excluded, cilta-cel, ciltacabtagene autoleucel; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30-item; LS, least squares; M, month: SOC, standard of care. 1. King MT, Qual Life Res 1996;5:555-67. 2. Osoba D, et al. / Clin Oncol 1998;16:139-44.



Effects of idecabtagene vicleucel versus standard regimens on health-related quality of life in patients with relapsed/refractory multiple myeloma who had received 2-4 prior regimens: updated results from the phase 3 KarMMa-3 trial

Michel Delforge,¹ Krina K. Patel,² Laurie Eliason,³ Devender Dhanda,³ Ling Shi,⁴ Shien Guo,⁴ Thomas S. Marshall,³ Bertrand Arnulf,⁵ Michele Cavo,⁶ Ajay K. Nooka,⁷ Salomon Manier,⁸ Natalie S. Callander,⁹ Sergio A. Giralt,¹⁰ Hermann Einsele,¹¹ Sikander Ailawadhi,¹² Mihaela Popa-McKiver,³ Mark Cook,¹³ Paula Rodríguez-Otero¹⁴


¹University Hospital Leuven, Leuven, Belgium; ²The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ³Bristol Myers Squibb, Princeton, NJ, USA; ⁴Evidera, Bethesda, MD, USA; ⁵Hôpital Saint-Louis, Paris, France; ⁶Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy; ⁷Winship Cancer Institute, Emory University, Atlanta, GA, USA; ⁸Centre Hospitalier Universitaire de Lille, Lille, France; ⁹University of Wisconsin Health Carbone Cancer Center, Madison, WI, USA; ¹⁰Memorial Sloan Kettering Cancer Center, New York, NY, USA; ¹¹Medizinische Klinik und Poliklinik II, Uniklinikum Würzburg, Würzburg, Germany; ¹²Mayo Clinic, Jacksonville, FL, USA; ¹³Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland; ¹⁴Clínica Universidad de Navarra, Pamplona, Spain

PRO instruments

	EORTC QLQ-C30 (15 domains)	EORTC QLQ-MY20 (4 domains)	EQ-5D-5L (2 domains)
Prespecified primary domains	GHS/QoL, physical and cognitive functioning, fatigue, pain	Disease symptoms and treatment AEs	VAS
Exploratory domains	Role, social, and emotional functioning, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties	Future perspectives Body image	UI; derived based on scores for 5 dimensions
Scale range	0-100	0-100	VAS: 0-100 UI: 0-1
Interpretation	↑ GHS and functioning domain scores = ↑ HRQoL ↑ Symptom domain scores = ↑ symptomatology or problems	 † Future perspectives/body image domain scores = † HRQoL † Symptom/side effects domain scores = † symptomatology or problems 	VAS: 0 = worst imaginable health; 100 = best imaginable health UI: 0 (death) - 1 (full health); negative = state perceived to be worse than death

AE, adverse event; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; EORTC QLQ-MY20, European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire; EQ-5D-5L, EuroQol 5 dimensions 5 levels; GHS, global health status; QoL, quality of life; UI, utility index; VAS, visual analogue scale.

Changes in overall HRQoL from baseline^a




MID, minimally important difference.

Delforge M, et al. ASH 2023 [Abstract #96]

KarMMa-3



American Society of Hematology Helping hematologists conquer blood diseases worldwide



Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Danai Dima, James A. Davis, Nausheen Ahmed, Xuefei Jia, Aishwarya Sannareddy, Hira Shaikh, Leyla Shune, Gurbakhash Kaur, Jack Khouri, Aimaz Afrough, Christopher Strouse, Jonathan Lochner, Zahra Mahmoudjafari, Shahzad Raza, Jason Valent, Larry D. Anderson, Jr, Faiz Anwer, Al-Ola Abdallah, **Hamza Hashmi**

US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS, USA Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland OH, USA Department of Hematology-Oncology, Medical University of South Carolina, Charleston, SC, USA Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA Division of Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA,USA

Results: Response to Teclistamab

Response (Full Cohort) N (%)	RWE cohort N=104	MajesTec-1 N=165
Overall response rate	70 (66)	104 (63)
Complete response or better	31 (29)	65 (39.4)
Very good partial response	18 (17)	32 (19.4)
Partial response	21 (20)	7 (4.2)
Minimal response	0	2 (1.2)
Stable disease	10 (9.5)	27 (16.4)
Progressive disease	26 (24.5)	24 (14.5)
Not evaluable	0	8 (4.8)

Subgroups of Interest	ORR, N (%)
Age>70 (n=34)	24 (71)
Non-Hispanic Black (n=28)	20 (71)
Pts ineligible for MajestEC-1 trial (n=88)	53 (60)
High-risk cytogenetics (n=56)	35 (63)
Triple Refractory (n=97)	62 (64)
Penta refractory (n=68)	46 (68)
Prior BCMA therapy	33 (59)
R-ISS III (n=25)	13 (52)
EMD (n=45)	21 (47)
Four or less prior LOT (n=26)	21 (81)
>4 lines of prior therapy (n=80)	49 (61)



Safety: Infections

No. of patients who developed infection	N=33 (31)
Total Number of Infections	39
Severe infections	18 (46)
Infections of the respiratory system	27 (69)
Bacterial infections	16 (41)
Viral infections	20 (51)
Fungal Infections	3 (3)
Onset, days, median	46 (1-218)

Subsequent Hospitalizations while on Teclistamab:

Cause of Hospitalization	Total Hospital Admissions = 28
Infection	16
Cytopenia	3
Symptom control	6
Neurotoxicity	2
Acute Kidney Injury	1

Severe Infections	Total =18
Unspecified bacterial pneumonia	2
Unspecified bacterial colitis	1
Unspecified bacterial sepsis	1
Enterobacter cloacae bacteremia	1
Parainfluenza	1
Respiratory syncytial virus	2
Metapneumovirus	2
Rhino & adenovirus pneumonia	1
Covid-19 infection	4
Unspecified viral respiratory infection	1
Aspergillus pneumonia	1
Candida guilliermondii fungemia	1

Three pts died from severe infection while on TEC: 1 from COVID-19 pneumonia, 1 from rhino/adenovirus pneumonia and 1 from sepsis





American Society of Hematology Helping hematologists conquer blood diseases worldwide


Cumulative incidence and characteristics of infections requiring treatment, delay in treatment administration or hospitalisation in patients with relapsed or refractory multiple myeloma treated with anti BCMA or anti GPRC5D bispecific antibodies.

<u>Elise Cellerin</u>^{*} and Aurélie Jourdes ^{*}, Xavier Brousse, Nicolas Vallet, Tom Cartau, Blandine Denis, Stephanie Harel, Simon Jamard, Alexis Redor, Titouan Cazaubiel, Virginie Roland, Carine Caleteix, Morgane Charles, Pierre Berger, Guillaume Escure, Aude Collignon, Emmanuel Faure, Clarisse Cazelles, Fanny Lanternier, Clementine de La Porte Des Vaux, Laurent Frenzel, Mathieu Blot, Francois Danion, Cécile Sonntag, Cyrille Touzeau, Andrea Pieragostini, Florence Ader, Lionel Karlin, Margaret Macro, Guillaume Martin-Blondel, Thomas Chalopin, Aurore Perrot – IFM study

Method

Intergroupe Francophone du Myélome centers (n=14)

All Relapsed/Refractory Multiple Myeloma treated with bispecific antibodies






Hospitalization

Specific treatment

Infections impacting patient management



Adaptation in BsAb administration




American Society of Hematology

Results




Identify associated variables - First infections


Univariate exploratory analysis



AdposenHighereriskofainfections with steroids for HR (95%C) CRS/ICANS 201 (1.27-3.19) • p=oSpacing of injections Does not lose efficacy (Usmani et al)



American Society of Hematology



MGUS





Revised Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance: Results of the iStopMM Study

Thorir Einarsson Long, Saemundur Rognvaldsson, Sigrun Thorsteinsdottir, Ingigerdur Solveig Sverrisdottir, Elias Eythorsson, Olafur Skuli Indridason, Runolfur Palsson, Thor Aspelund, Brynjar Vidarsson, Pall Torfi Onundarson, Bjarni Agnar Agnarsson, Margret Sigurdardottir, Ingunn Thorsteinsdottir, Isleifur Olafsson, Asdis Rosa Thordardottir, Asbjorn Jonsson, Gauti Gislason, Andri Olafsson, Malin Hultcrantz,

Brian G.M. Durie, Stephen Harding, Thorvardur Jon Love, Ola Landgren, and Sigurdur Yngvi Kristinsson

University of Iceland, Reykjavik, Iceland; Skane University Hospital, Lund, Sweden; Lund University, Lund, Sweden; Rigshospitalet, Copenhagen, Denmark; Sahlgrenska University Hospital, Gothenburg, Sweden; Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland; Akureyri Hospital, Akureyri, Iceland; Memorial Sloan Kettering Cancer Center, New York, NY; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA; Binding Site Group Ltd., Birmingham, United Kingdom; University of Miami, Sylvester Comprehensive Cancer Center, Miami.

iStopMM – Renal reference intervals

	Γ	New reference interval	S
Kidney function (mL/min/1.73 m ²)	Kappa (mg/L)	Lambda (mg/L)	FLC ratio
eGFR 45– 59 N=4612	7.8 – 83.6	7.3 – 65.1	0.46 - 2.62
eGFR 30–44 N=1465	8.8 – 103.3	8.2 – 73.2	0.48 – 3.38
eGFR < 30 N=384	11.7 – 265.1	12.6 – 150.9	0.54 – 3.30

Long et al. Blood Cancer J, 2022, "Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study"





Aims

Assess the distribution of kappa, lambda, and the FLC ratio in terms of standard reference intervals. Revise FLC reference intervals in individuals with preserved kidney function (eGFR >60 mL/min/1.73 m²) and propose a new definition of light chain MGUS.





Revised reference intervals for persons with preserved kidney function (eGFR $\geq 60 \text{ mL/min}/1.73 \text{m}^2$)


	Γ	lew reference interval	S
Age category	Kappa (mg/L)	Lambda (mg/L)	FLC ratio
Age < 70 years N=33,181	6.3 – 39.0	5.9 – 36.7	0.44 - 2.16
Age 70 years and above N=8,701	7.0 – 55.8	6.4 - 48.0	0.46 – 2.59






Prevalence of LC MGUS

- Prevalence of LC MGUS in the iStopMM cohort (N=75,422) based on novel definition was 0.26% (95%CI: 0.23-0.30%).
- Prevalence using the standard definition was 1.54% (95%CI: 1.46-1.63%).
- Relative decrease of 83%, of whom none progressed to lymphoproliferative disorder after a median 3.5 year follow-up.







Light chain MGUS calculator

Serum free kappa, mg/L		
Serum free lambda, r	ng/L	
15		
Age, years		
73		
GFR* mL/min/1.73m	12	
62	\$	

Scan me!



FLC (free light chain ratio) is 4.2 Based on the information provided **this person has light chain monoclonal** gammopathy of undetermined significance (LC-MGUS)

* Serum creatinine based CKD-EPI eGFR equation (2009) was used in the study where these reference intervals were determined. This calculator was developed based on measurments using the Freelite assay.





https://istopmm.com/lcmgus/




American Society of Hematology Helping hematologists conquer blood diseases worldwide



Primary Care Management Pathways to Reduce Wait Times in Hematology: Monoclonal Gammopathy of Undetermined Significance

P. Ganguli MD, J. Dyba MD, A. E. Hay MB ChB, L. Zhang PhD, S.A. Silver MD, MSc, Y. Huang PhD, K. Loughlin MD, E. Eisenhauer MD, B. Monteith MD, MSc Queen's University, Canada



- Hemoglobin <100g/L
- Calcium > 2.75 mmol/L
- eGFR < 45 ml/min/1.72/m²
- · Lytic bone lesions
- Urine M-protein > 500mg/24hours
- sFLC ratio > 8 or <0.125

Referral Contact Details

Details provided to contact attending Hematologist for **emergency referrals** of a pathway patient


Do you have a question regarding a patient on the pathway?

Details provided to contact attending Hematologist for **non-urgent questions** regarding a pathway patient


Instructions provided to consider eConsult if there are questions about patients who do not meet pathway criteria for a referral.



American Society of Hematology



Median Monthly MGUS Wait Times For Patients Seen January 2021- December 2022 Key Points



Thank you Questions?

@Ashley_Rosko1

Ashley.Rosko@osumc.edu

